Clinical trial · Observational
Selpercatinib and Body Composition
NCT07543887CI-TRIAL-00109106EECRTKIcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
investigation of body composition
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| observation in patient under treatment | Other | — | UNRESOLVED |
| Selpercatinib | Drug | Selpercatinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- patient with advanced medullary thyroid cancer
- description
- patient with advanced medullary thyroid cancer
- interventionNames
- Other: observation in patient under treatment
- Drug: Selpercatinib
Primary outcomes (1)
- measure
- Total lean mass assessed by DXA (kg)
- timeFrame
- Baseline and 12 months
- description
- Total lean body mass measured by dual-energy X-ray absorptiometry
Secondary outcomes (1)
- measure
- 24-hour energy expenditure (kcal/day)
- timeFrame
- Baseline and 12 months
- description
- Total energy expenditure measured over 24 hours using a whole-room indirect calorimeter
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Adults (≥18 years old) * Diagnosis of thyroid cancer * Ongoing treatment with selpercatinib Exclusion Criteria: \- Inability to provide informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.